|
Cypress Bioscience,
Inc.
CYPB develops, manufactures and markets medical devices for the treatment and diagnosis of certain immune-mediated diseases, transplantations and cancers. The Company is a leader in the field of immunoadsorption treatment, and under its new management team, is aggressively moving to capitalize on its technology and management expertise through both internal initiatives and add-on acquisitions, strategic in-licensing and corporate partnerships. The Company manufactures and markets its FDA approved PROSORBA column for the treatment of idiopathic thrombocytopenic purpura ("ITP"), an immune-mediated bleeding disorder that affects approximately 500,000 people in the US and Europe. In October 1996, the Company acquired PRP, Inc., a biopharmaceutical company engaged in the development of novel therapeutic agents for the treatment of blood platelet disorders. SMALLCAPS RESEARCH
|